Cocrystal Pharma, Inc. (COCP) - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on October 27, 2025, by Cocrystal Pharma, Inc., a Delaware corporation. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding a new funding award received by the company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a non-financial operational milestone rather than periodic financial results.
Material Changes and Events
- SBIR Phase I Award: On October 27, 2025, the Company announced it received a Small Business Innovation Research (SBIR) Phase I award.
- Awarding Agencies: The award was granted by the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID).
- Significance: This award represents external validation of the Company's research and provides non-dilutive funding for its development programs.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer that the press release information is not deemed "filed" under Section 18 of the Exchange Act. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the specific dollar amount of the SBIR Phase I award by reviewing the attached press release (Exhibit 99.1).
- Confirm the specific research project or therapeutic area targeted by the NIH/NIAID award.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not provide those figures.